journal
MENU ▼
Read by QxMD icon Read
search

Annals of Translational Medicine

journal
https://www.readbyqxmd.com/read/29666820/together-we-witness-the-5-th-ame-journal-indexed-in-scie-annals-of-translational-medicine
#1
(no author information available yet)
No abstract text is available yet for this article.
March 2018: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29666819/the-surgeon-thunderbolts-in-2016-lung-cancer-literature
#2
EDITORIAL
Luca Bertolaccini, Alessandro Pardolesi, Jury Brandolini, Piergiorgio Solli
No abstract text is available yet for this article.
March 2018: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29666818/the-role-of-positron-emission-tomography-in-the-diagnosis-staging-and-response-assessment-of-non-small-cell-lung-cancer
#3
REVIEW
Sara Volpi, Jason M Ali, Angela Tasker, Adam Peryt, Giuseppe Aresu, Aman S Coonar
Lung cancer is a common disease and the leading cause of cancer-related mortality, with non-small cell lung cancer (NSCLC) accounting for the majority of cases. Following diagnosis of lung cancer, accurate staging is essential to guide clinical management and inform prognosis. Positron emission tomography (PET) in conjunction with computed tomography (CT)-as PET-CT has developed as an important tool in the multi-disciplinary management of lung cancer. This article will review the current evidence for the role of 18 F-fluorodeoxyglucose (FDG) PET-CT in NSCLC diagnosis, staging, response assessment and follow up...
March 2018: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29666817/surgical-approach-in-the-oligometastatic-patient
#4
REVIEW
Duilio Divisi, Mirko Barone, Gino Zaccagna, Francesca Gabriele, Roberto Crisci
In the setting of a stage IV non-small cell lung cancer (NSCLC), oligometastatic patients represent a heterogeneous group whose incidence is increasing as far as with the adoption of new therapeutic regimens, the improvement of the molecular characterization assays and the increasing number of long-survivor patients. The oligometastatic state undergone a major revision with the introduction of the new TNM lung cancer staging system, being characterized by a different prognosis compared to multi-metastatic patients...
March 2018: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29666816/surgical-approach-in-oligometastatic-non-small-cell-lung-cancer
#5
REVIEW
Davide Patrini, Nikolaos Panagiotopoulos, Benedetta Bedetti, Sofoklis Mitsos, Roberto Crisci, Piergiorgio Solli, Luca Bertolaccini, Marco Scarci
The vast majority of lung cancer (80%) are non-small cell lung cancer (NSCLC) presenting in huge proportion of patients in a metastatic stage at the time of diagnosis with an overall survival (OS) of only 6 months. Standard treatment at this stage involves systemic platinum based chemotherapy improving the OS for only few months. For the vast majority of patients disease progression occurs and cure cannot achieved. An exception to this general rule is represented by patients with a limited number of metastasis (approximately 7% of patients with metastatic NSCLC): in 1995 Hellman and Weichselbaum introduced the term "oligometastatic" for a selected group of patients with metastatic disease...
March 2018: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29666815/endobronchial-ultrasound-transbronchial-needle-aspiration-ebus-tbna-a-diagnostic-challenge-for-mediastinal-lesions
#6
REVIEW
Duilio Divisi, Gino Zaccagna, Mirko Barone, Francesca Gabriele, Roberto Crisci
Lung cancer is one of the most frequent neoplastic diseases. To date, most lung cancer is diagnosed at an advanced stage, making it difficult to choose the diagnostic and therapeutic strategy. Surgical resection represents the best therapeutic solution. However, the best results are obtained only in the early stages of the disease. Lymph node involvement conditions the treatment (surgical or non-surgical approach). Mediastinoscopy is an effective and widely used method for mediastinal staging but does not allow us to reach many mediastinal lymph nodes...
March 2018: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29666814/digital-chest-tomosynthesis-the-2017-updated-review-of-an-emerging-application
#7
REVIEW
Arianna Ferrari, Luca Bertolaccini, Piergiorgio Solli, Paola Oriana Di Salvia, David Scaradozzi
Lung cancer is the leading cause of cancer death and second most common cancer among both men and women, but most of them are detected when patients become symptomatic and in late-stage. Chest radiography (CR) is a basic technique for the investigation of lung cancer and has the benefit of convenience and low radiation dose, but detection of malignancy is often difficult. The introduction of computed tomography (CT) for screening has increased the proportion of lung cancer detected but with higher exposure dose and higher costs...
March 2018: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29666813/ground-glass-opacities-management-in-the-lung-cancer-screening-era
#8
REVIEW
Marcello Migliore, Mariaconcetta Fornito, Manuela Palazzolo, Alessandra Criscione, Mariapia Gangemi, Francesco Borrata, Paolo Vigneri, Marco Nardini, Joel Dunning
Pulmonary ground glass opacity (GGO) is becoming an important clinical dilemma in oncology as its diagnosis in clinical practice is increasing due to the introduction of low dose computed tomography (CT) scan and screening. The incidence of cancer in GGO has been reported as high as 63%. The purpose of this manuscript is to review best available evidence papers on management of GGO in lung cancer to address the following questions: (I) how to correlate CT findings with malignancy; (II) when and who operate? (III) how to perform intraoperative detection of intrapulmonary GGO? (IV) wedge, segmentectomy or lobectomy? Taking a cue from a clinical scenario, a review on PubMed was conducted...
March 2018: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29666812/tumor-progression-the-neuronal-input
#9
REVIEW
Marco Arese, Federico Bussolino, Margherita Pergolizzi, Laura Bizzozero, Davide Pascal
One of the challenges of cancer is its heterogeneity and rapid capacity to adapt. Notwithstanding significant progress in the last decades in genomics and precision medicine, new molecular targets and therapies appear highly necessary. One way to approach this complex problem is to consider cancer in the context of its cellular and molecular microenvironment, which includes nerves. The peripheral nerves, the topic of this review, modulate the biological behavior of the cancer cells and influence tumor progression, including the events related to the metastatic spread of the disease...
March 2018: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29666811/immune-checkpoint-pathways-in-non-small-cell-lung-cancer
#10
REVIEW
Young Kwang Chae, Ayush Arya, Wade Iams, Marcello Cruz, Nisha Mohindra, Victoria Villaflor, Francis J Giles
Immunotherapy has evolved at a phenomenal pace in cancer therapeutics. This has primarily been fueled by the much perceived necessity to procure an alternative to current standard of care chemotherapy agents, owing to several concerns such as treatment-related toxicity and poor long-term survival associated with the same. The knowledge of various mechanisms involved in regulation of immune response to cancer cells has served a fundamental role in identifying key molecules through which immune cell activity may be modulated...
March 2018: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29666810/the-8-th-tnm-edition-for-lung-cancer-a-critical-analysis
#11
REVIEW
Paul E Van Schil, Ramon Rami-Porta, Hisao Asamura
The 8th edition of the tumor, node and metastasis (TNM) classification provides several new categories and for the first time, some prospective data are included. The T (tumor) descriptor is further subdivided with 1 cm increments for T1 and T2 disease. For metastatic disease (M descriptor) the new M1b category comprises patients with only one metastasis in one distant organ, whereas M1c implies multiple distant metastases in one or several organs. There are no changes regarding the nodal map and N component but new categories are suggested for further analysis, subdividing the N1 and N2 descriptors into involvement of single or multiple lymph node stations...
March 2018: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29666809/lung-cancer-update-2017-from-the-test-tube-to-the-bed
#12
Luca Bertolaccini, Federico Cappuzzo, Piergiorgio Solli
No abstract text is available yet for this article.
March 2018: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29666808/oncological-outcomes-of-the-time-trial-in-esophageal-cancer-is-it-the-era-of-minimally-invasive-esophagectomy
#13
EDITORIAL
Lijie Tan, Han Tang
No abstract text is available yet for this article.
February 2018: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29666807/quality-of-life-assessment-in-esophagectomy-patients
#14
REVIEW
Alla Alghamedi, Gordon Buduhan, Lawrence Tan, Sadeesh Kumar Srinathan, Joanne Sulman, Gail Darling, Biniam Kidane
Esophagectomy is the mainstay of curative therapy for esophageal cancer; however, it is associated with significant morbidity and mortality, with subsequent major impact on quality of life. This paper reviews the evaluation of health-related quality of life (HRQOL) in esophageal cancer patients undergoing curative intent therapy, the relationship between postoperative HRQOL and survival as well the potential utility of pre-treatment HRQOL as a prognostic tool. HRQOL assessment is valuable in helping clinicians understand the impact on patients of esophageal cancer and the various treatments thereof...
February 2018: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29666806/the-frontline-of-esophageal-cancer-treatment-questions-to-be-asked-and-answered
#15
REVIEW
Cheng-Che Tu, Po-Kuei Hsu
Achieving a good treatment for esophageal cancer is a great challenge. For early stage cancer, endoscopic treatment is considered the first line and a possible curative therapy. Chemotherapy, radiotherapy, and surgery are all used for the treatment of locally advanced esophageal cancer, administered either alone or combined. Some combinations have proven to be feasible, effective, and superior, such as neoadjuvant chemoradiation (CRT) plus surgery in the Chemoradiotherapy for Oesophageal Cancer Followed by Surgery Study (CROSS) trial...
February 2018: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29666805/surveillance-or-resection-after-chemoradiation-in-esophageal-cancer
#16
REVIEW
Il-Hwan Park, Jae Y Kim
The treatment of locally advanced esophageal cancer continues to evolve. Previously, surgery was considered the foundation of treatment, but chemoradiation (CRT) has taken on a larger role both in the neoadjuvant setting and as definitive treatment. It has become clear that although some patients benefit from esophagectomy after CRT, a large subset of patients likely derive no benefit, and may be harmed by surgery. Some patients are cured from CRT alone and therefore do not need surgery. Another group of patients likely have metastatic disease at the time of local therapy that is just undetected on imaging and also do not benefit from surgery...
February 2018: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29666804/surveillance-versus-esophagectomy-in-esophageal-cancer-patients-with-a-clinical-complete-response-after-induction-chemoradiation
#17
REVIEW
Tara R Semenkovich, Bryan F Meyers
There currently exists an area of controversy in treatment of esophageal cancer for patients who have an apparent clinical complete response (cCR) after induction chemoradiation. A standard treatment is to offer these patients an esophagectomy, but increasingly there is interest from both the patient and provider for active surveillance with so-called "salvage" esophagectomies for local recurrence as an alternative treatment paradigm. In this article, we review the existing evidence that stakeholders should consider for clinical decision-making in this specific patient population, including: the accuracy of post-induction clinical restaging, the reliability of operative risk assessment, the feasibility and adherence to surveillance strategies, and the observed outcomes in these patients after salvage esophagectomy or continued active surveillance...
February 2018: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29666803/personalized-therapy-based-on-image-for-esophageal-or-gastroesophageal-junction-adenocarcinoma
#18
REVIEW
Kazuto Harada, Dilsa Mizrak Kaya, Anthony Lopez, Hideo Baba, Jaffer A Ajani
Preoperative therapy is the gold standard for esophageal or gastroesophageal junction adenocarcinoma. Positron emission tomography (PET) is not only essential for tumor staging, but changes in glucose consumption correspond with response to therapy and correlated with prognosis. Therefore, with further refinement, PET parameter can serve as a tool for personalized therapy. For instance, the Municon trials suggested the possibility of PET-response guided therapy for esophageal adenocarcinoma (EAC) patients, however there are limitations...
February 2018: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29666802/advances-in-radiotherapy-for-esophageal-cancer
#19
REVIEW
Wei Deng, Steven H Lin
Esophageal cancer is a common type of malignancy worldwide and usually requires multidisciplinary care. Radiotherapy plays an important part in management of the disease. During the past few years, researchers have made much progress about radiotherapy for esophageal cancer, which was revealed in every aspect of clinical practice. Neoadjuvant chemoradiotherapy remains the standard treatment for locally advanced esophageal cancer, whereas neoadjuvant chemotherapy appears to show less toxicities and non-inferior prognosis...
February 2018: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29666801/current-therapeutic-landscape-for-advanced-gastroesophageal-cancers
#20
REVIEW
Anthony Lopez, Kazuto Harada, Dilsa Mizrak Kaya, Jaffer A Ajani
Treatment of advanced gastroesophageal cancers remains challenging for clinicians, patients, and caregivers alike. Despite considerable research, the therapeutic armamentarium is restricted and hardly personalized. In the first-line setting, trastuzumab with a fluoropyrimidine and platinum agent is the standard-of-care in patients with HER2-positive tumor. For the others, a platinum-based doublet (preferably with oxaliplatin) is recommended. Three-drug cytotoxic regimens should be reserved for exceptional cases where patients have good performance status...
February 2018: Annals of Translational Medicine
journal
journal
48269
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"